Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide (PCP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01166113 |
Recruitment Status
:
Active, not recruiting
First Posted
: July 20, 2010
Last Update Posted
: September 6, 2017
|
Sponsor:
Fondazione Neoplasie Sangue Onlus
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Actual Primary Completion Date : | June 2011 |
Estimated Study Completion Date : | July 2018 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):